[{"indications": "Indications\u00a0hyperlipidaemias of types IIa, IIb, III, IV, and V in patients who\r\nhave not responded adequately to diet and other appropriate measures;\r\nalso see notes above", "name": "BEZAFIBRATE", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.12 Lipid-regulating drugs", "Fibrates", "BEZAFIBRATE"], "cautions": "Cautions\u00a0correct hypothyroidism before initiating treatment (see Lipid-regulating drugs); interactions: Appendix 1 (fibrates)", "side-effects": "Side-effects\u00a0gastro-intestinal disturbances, anorexia; less commonly cholestasis, weight gain, dizziness, headache,\r\nfatigue, drowsiness, renal impairment, raised serum creatinine (unrelated\r\nto renal impairment), erectile dysfunction, myotoxicity (with myasthenia\r\nor myalgia)\u2014special risk in renal impairment (see Cautions), urticaria,\r\npruritus, photosensitivity reactions; very rarely gallstones, hypoglycaemia, anaemia, leucopenia, thrombocytopenia,\r\nincreased platelet count, alopecia, Stevens-Johnson syndrome, and\r\ntoxic epidermal necrolysis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/85737.htm", "doses": ["See preparations below"], "pregnancy": "Pregnancy\u00a0manufacturers advise avoid\u2014embryotoxicity in animal studies"}, {"indications": "Indications\u00a0hyperlipidaemias of types IIa, IIb, III, IV, and V in patients who\r\nhave not responded adequately to diet and other appropriate measures;\r\nalso see notes above", "name": "BEZAFIBRATE Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "2 Cardiovascular system", "2.12 Lipid-regulating drugs", "Fibrates", "BEZAFIBRATE", "Modified release"], "cautions": "Cautions\u00a0correct hypothyroidism before initiating treatment (see Lipid-regulating drugs); interactions: Appendix 1 (fibrates)", "side-effects": "Side-effects\u00a0gastro-intestinal disturbances, anorexia; less commonly cholestasis, weight gain, dizziness, headache,\r\nfatigue, drowsiness, renal impairment, raised serum creatinine (unrelated\r\nto renal impairment), erectile dysfunction, myotoxicity (with myasthenia\r\nor myalgia)\u2014special risk in renal impairment (see Cautions), urticaria,\r\npruritus, photosensitivity reactions; very rarely gallstones, hypoglycaemia, anaemia, leucopenia, thrombocytopenia,\r\nincreased platelet count, alopecia, Stevens-Johnson syndrome, and\r\ntoxic epidermal necrolysis", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/2846.htm", "doses": ["See preparations below", "Name[Bezalip\u00ae Mono (Actavis) ] Tablets, m/r, f/c, bezafibrate 400\u00a0mg, net price 30-tab pack = \u00a37.63. \r\n    Label:\r\n    21, 25Dose\u00a0400\u00a0mg once daily (dose form not appropriate in patients\r\nwith renal impairment)"], "pregnancy": "Pregnancy\u00a0manufacturers advise avoid\u2014embryotoxicity in animal studies"}]